JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4135 Tofacitinib (CP-690550) Citrate
2 Citation

Target: JAK

Summary: Potent JAK inhibitor

≥25.22 mg/mL
A4136 TG101348 (SAR302503)
2 Citation

Target: FLT3|JAK|c-RET

Summary: JAK-2 inhibitor,potent and selective

≥26.23 mg/mL
A4137 AZD1480

Target: JAK

Summary: JAK2 inhibitor,ATP-competitive and novel

insoluble in H2O; ≥93.8 mg/mL
A4140 WP1066

Target: STAT|JAK

Summary: JAK2/STAT3 inhibitor,cell-permeable

insoluble in H2O; ≥17.8 mg/mL
A4144 AZ 960

Target: JAK

Summary: JAKs inhibitor

Soluble in DMSO
A4147 LY2784544

Target: Aurora Kinases|FLT3|VEGFR|FGFR|Trk Receptors|JAK|ALK|TYK2|MUSK|MAP3K

Summary: JAK2 inhibitor,highly potent and selective

≥23.5 mg/mL
A4149 S-Ruxolitinib (INCB018424)

Target: JAK

Summary: JAK1/2 inhibitor,potent and selective

Soluble in DMSO
A4150 WHI-P154

Target: VEGFR|Src|EGFR|JAK

Summary: JAK3 inhibitor

insoluble in H2O; insoluble in EtOH; ≥125.6 mg/mL
A4124 TAK-901

Target: Aurora Kinases|FLT3|Src|JAK|LRRK2|Hck|FGR|YES|Fyn|ARG

Summary: Novel Aurora A/B inhibitor

≥25.25 mg/mL